BEAM - CRISPR Therapeutics's Leading Thalassemia And Sickle Cell Disease Investigational Therapy
- CRSP's leading investigational therapy CTX001's mode of action creates a situation where the company is killing two birds with one stone, treating both beta-thalassemia and sickle cell disease patients.
- Although the beta-thalassemia market size is small, the combined patient pool of Sickle Cell Disease and beta-thalassemia is enough for a commercially viable launch once the therapy is approved.
- The latest update on CTX001 was in December last year. Given the trial's three-month endpoint, investors should expect an update for the newly enrolled patients soon.
For further details see:
CRISPR Therapeutics's Leading Thalassemia And Sickle Cell Disease Investigational Therapy